Team
Leadership team
Dr. Sarvesh Malviya Jain
(Managing Director & Chief Executive Officer)
Mr. Sandeep Jain
Mr.Sandeep has 11+ years of experience in pharmaceutical industry. His business acumen, entrepreneurial zeal, organizational skills and managerial abilities have enabled Oniosome to grow leaps and bounds and spread its wings across the globe.
He set out with a vision to create a global pharmaceutical company. Under his able and dynamic leadership, Oniosome has grown rapidly to attain newer milestones and the highest level of performance. He is the principal architect for the progress of the organization.
Mr.Sandeep is M. Pharm (Pharmaceuticals) graduate for about one decades of experience across Research & Development. He is well versed with the overall management of the company and possesses vast amount of hands-on experience in research and formulation development.
Ms. Jagjiwandeep Kapoor
Ms.Kapoor has 20+ years of experience in Vaccine manufacturing (APIs) covering Production planning, GMP Trainings, Internal audits (technical and GMP), Quality Assurance and Designing Process scale-up strategies. She has a special interest in trainings and enablement in the field of Biotechnology and involved in various training program as a lead trainer.
Ms.Kapoorhas served roles of increasing responsibilities with one of the leading Indian Bio-pharmaceutical Organization Panacea Biotech Private Limited and later with Global pharmaceutical giant Merck, wherein she was responsible to fully engage the emerging markets and local cultural aspects of Asia and realize technical sourcing opportunities, leading strategic regional projects, clarifying, or developing risk and mitigation strategies.
Ms.Kapoorholds a Post Graduate Degree (M.Sc. Biotechnology) from Thapar Institute of Engineering and Technology, Patiala, Punjab and has deep interest in bioprocess development and lean management. She is an expert in downstream processing of proteins, vaccines formulations& QMS and has played an instrumental in WHO prequalification of recombinant, conventional and Polysaccharide-conjugate vaccines.
